FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038100737> ?p ?o ?g. }

• W2038100737 abstract "Background: The management of early breast cancer (BC) continues to be challenging because of the heterogeneity of the disease and a limited number of clinical/pathological factors are currently used to guide therapy and prognosis. Recently, p53, a tumor suppressor and BCL2, an antiapoptotic protein have been proposed as additional prognostic markers, although their relationship with conventional parameters and patient prognosis remains uncertain. In particular, there are few data concerning p53 and BCL2 distribution within the molecular BC subtypes, luminal A (LA), luminal B/HER2- (LB/HER2-), luminal B/HER2+ (LB/HER2+), HER2-like (H), and triple negative (TN).Methods: We conducted a retrospective study using immunohistochemistry to evaluate p53 and BCL2 expression in 1099 early BC patients (median age 56 yrs [21-92], N+ 487 [45%]) surgically treated at our Institute between 2000 and 2006 with at least 5 yrs follow-up data. None of the HER2+ patients, included in our series, received trastuzumab in the adjuvant setting. Associations among p53 and BCL2, T, N, G and molecular subtypes were analyzed by multiple correspondence analysis (MCA), while Kaplan-Meier method was applied to determine their impact on disease-free survival (DFS).Results: p53 and BCL2 differently distribute across the 5 molecular subtypes (p-value<0.0001). p53 is highly positive in LB-H+ (38%), H (50%) and TN (33%), conversely, BCL2 is more frequently expressed in LA (71%) and LB-H- (75%) BC. The relationships among bio-pathological factors, analyzed by MCA, confirmed that p53 positive and BCL2 negative BC are located in the quadrant containing more aggressive conventional tumor phenotypes (H and TN subtypes, T3/T4, N+, G3 and presence of relapse). Kaplan-Meier curves identified BCL2 negativity as a significant discriminating factor for DFS (p = 0.024) while p53 does not discriminate BC patients independent of molecular subtypes. Of interest, in the subset of 595 N0 patients p53 positivity and BCL2 negativity were significantly associated to the lack of response to anthracycline (AC ± taxanes) based chemotherapy (p<0.0001). Focusing on the 345 BC who relapsed (132 visceral and 213 non visceral metastases) we observed that visceral metastases are significantly less frequent in LA (30%), LB HER2- (37%) and TN (29%) BC as compared to H (52%) and LB-HER2+ (58%) BC (p = 0.004).Conclusions: Our data indicated that lack of BCL2, in contrast to p53 positivity, appears to be a biomarker related to a more aggressive clinical course across BC molecular subtypes although both biomarkers may affect AC-based chemotherapy response in the subset of N0 patients. Visceral metastases are more frequent in H and LB-HER+ subtypes as compared to the other groups.Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-05-16." @default.
• W2038100737 created "2016-06-24" @default.
• W2038100737 creator A5003794698 @default.
• W2038100737 creator A5024297793 @default.
• W2038100737 creator A5025910266 @default.
• W2038100737 creator A5028866303 @default.
• W2038100737 creator A5029752400 @default.
• W2038100737 creator A5030601208 @default.
• W2038100737 creator A5030864893 @default.
• W2038100737 creator A5031725887 @default.
• W2038100737 creator A5034751834 @default.
• W2038100737 creator A5047254886 @default.
• W2038100737 creator A5050667278 @default.
• W2038100737 creator A5051546655 @default.
• W2038100737 creator A5058965359 @default.
• W2038100737 creator A5071451902 @default.
• W2038100737 creator A5071661973 @default.
• W2038100737 creator A5074002309 @default.
• W2038100737 creator A5074512020 @default.
• W2038100737 creator A5082849117 @default.
• W2038100737 creator A5083846073 @default.
• W2038100737 date "2013-12-15" @default.
• W2038100737 modified "2023-09-24" @default.
• W2038100737 title "Abstract P6-05-16: p53 and BCL2 expression across molecular subtypes: Correlation with disease progression, response to therapy and site of relapse in 1099 early breast cancer patients" @default.
• W2038100737 doi "https://doi.org/10.1158/0008-5472.sabcs13-p6-05-16" @default.
• W2038100737 hasPublicationYear "2013" @default.
• W2038100737 type Work @default.
• W2038100737 sameAs 2038100737 @default.
• W2038100737 citedByCount "0" @default.
• W2038100737 crossrefType "proceedings-article" @default.
• W2038100737 hasAuthorship W2038100737A5003794698 @default.
• W2038100737 hasAuthorship W2038100737A5024297793 @default.
• W2038100737 hasAuthorship W2038100737A5025910266 @default.
• W2038100737 hasAuthorship W2038100737A5028866303 @default.
• W2038100737 hasAuthorship W2038100737A5029752400 @default.
• W2038100737 hasAuthorship W2038100737A5030601208 @default.
• W2038100737 hasAuthorship W2038100737A5030864893 @default.
• W2038100737 hasAuthorship W2038100737A5031725887 @default.
• W2038100737 hasAuthorship W2038100737A5034751834 @default.
• W2038100737 hasAuthorship W2038100737A5047254886 @default.
• W2038100737 hasAuthorship W2038100737A5050667278 @default.
• W2038100737 hasAuthorship W2038100737A5051546655 @default.
• W2038100737 hasAuthorship W2038100737A5058965359 @default.
• W2038100737 hasAuthorship W2038100737A5071451902 @default.
• W2038100737 hasAuthorship W2038100737A5071661973 @default.
• W2038100737 hasAuthorship W2038100737A5074002309 @default.
• W2038100737 hasAuthorship W2038100737A5074512020 @default.
• W2038100737 hasAuthorship W2038100737A5082849117 @default.
• W2038100737 hasAuthorship W2038100737A5083846073 @default.
• W2038100737 hasConcept C121608353 @default.
• W2038100737 hasConcept C126322002 @default.
• W2038100737 hasConcept C142724271 @default.
• W2038100737 hasConcept C143998085 @default.
• W2038100737 hasConcept C204232928 @default.
• W2038100737 hasConcept C207886595 @default.
• W2038100737 hasConcept C2777982462 @default.
• W2038100737 hasConcept C2779134260 @default.
• W2038100737 hasConcept C2779786085 @default.
• W2038100737 hasConcept C3020813896 @default.
• W2038100737 hasConcept C50382708 @default.
• W2038100737 hasConcept C530470458 @default.
• W2038100737 hasConcept C71924100 @default.
• W2038100737 hasConceptScore W2038100737C121608353 @default.
• W2038100737 hasConceptScore W2038100737C126322002 @default.
• W2038100737 hasConceptScore W2038100737C142724271 @default.
• W2038100737 hasConceptScore W2038100737C143998085 @default.
• W2038100737 hasConceptScore W2038100737C204232928 @default.
• W2038100737 hasConceptScore W2038100737C207886595 @default.
• W2038100737 hasConceptScore W2038100737C2777982462 @default.
• W2038100737 hasConceptScore W2038100737C2779134260 @default.
• W2038100737 hasConceptScore W2038100737C2779786085 @default.
• W2038100737 hasConceptScore W2038100737C3020813896 @default.
• W2038100737 hasConceptScore W2038100737C50382708 @default.
• W2038100737 hasConceptScore W2038100737C530470458 @default.
• W2038100737 hasConceptScore W2038100737C71924100 @default.
• W2038100737 hasLocation W20381007371 @default.
• W2038100737 hasOpenAccess W2038100737 @default.
• W2038100737 hasPrimaryLocation W20381007371 @default.
• W2038100737 hasRelatedWork W1813546997 @default.
• W2038100737 hasRelatedWork W1978622260 @default.
• W2038100737 hasRelatedWork W1981578998 @default.
• W2038100737 hasRelatedWork W2002832859 @default.
• W2038100737 hasRelatedWork W2036152798 @default.
• W2038100737 hasRelatedWork W2056173816 @default.
• W2038100737 hasRelatedWork W2106304815 @default.
• W2038100737 hasRelatedWork W2116986258 @default.
• W2038100737 hasRelatedWork W2201663483 @default.
• W2038100737 hasRelatedWork W2247185831 @default.
• W2038100737 hasRelatedWork W2312533745 @default.
• W2038100737 hasRelatedWork W2414484209 @default.
• W2038100737 hasRelatedWork W2461334759 @default.
• W2038100737 hasRelatedWork W2463936553 @default.
• W2038100737 hasRelatedWork W2499474232 @default.
• W2038100737 hasRelatedWork W2792884341 @default.
• W2038100737 hasRelatedWork W2899496983 @default.
• W2038100737 hasRelatedWork W3007408275 @default.
• W2038100737 hasRelatedWork W3113469666 @default.
• W2038100737 hasRelatedWork W3149429589 @default.
• W2038100737 isParatext "false" @default.
• W2038100737 isRetracted "false" @default.

• next